Selective activation of group II mGluRs with LY354740 does not prevent neuronal excitotoxicity

被引:26
作者
Behrens, MM
Strasser, U
Heidinger, V
Lobner, D
Yu, SP
McDonald, JW
Won, M
Choi, DW
机构
[1] Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA
关键词
glutamate receptors; neuronal death; excitotoxicity;
D O I
10.1016/S0028-3908(99)00098-2
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Recent reports have suggested a role for group II metabotropic glutamate receptors (mGluRs) in the attenuation of excitotoxicity. Here we examined the effects of the recently available group II agonist (+)-2-Aminobicyclo[3. 1.0]hexane-2-6-dicarboxylic acid (LY354740) on N-methyl-D-aspartate (NMDA)-induced excitotoxic neuronal death, as well as on hypoxic-ischemic neuronal death both in vitro and in vivo. At concentrations shown to be selective for group II mGluRs expressed in cell lines (0.1-100 nM), LY354740 did not attenuate NMDA-mediated neuronal death in vitro or in vivo. Furthermore, LY354740 did not attenuate oxygen-glucose deprivation-induced neuronal death in vitro or ischemic infarction after transient middle cerebral artery occlusion in rats. In addition, the neuroprotective effect of another group II agonist, (S)-4-carboxy-3-phenylglycine (4C3HPG), which has shown injury attenuating effects both in vitro and in vive, was not blocked by the group II antagonists (2 S)-alpha-ethylglutamic acid (EGLU), (RS)-alpha-methyl-4-sulphonophenylglycine (MSPG), or the group III antagonist (S)-alpha-methyl-3-carboxyphenylalanine (MCPA), suggesting that this neuroprotection may be mediated by other effects such as upon group I mGluRs. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1621 / 1630
页数:10
相关论文
共 67 条
[1]   Role of group I metabotropic glutamate receptors in traumatic spinal cord white matter injury [J].
Agrawal, SK ;
Theriault, E ;
Fehlings, MG .
JOURNAL OF NEUROTRAUMA, 1998, 15 (11) :929-941
[2]  
AMBROSINI A, 1995, MOL PHARMACOL, V47, P1057
[3]   SELECTIVE ACTIVATION OF QUISQUALATE METABOTROPIC RECEPTOR POTENTIATES NMDA BUT NOT AMPA RESPONSES [J].
ANIKSZTEJN, L ;
BREGESTOVSKI, P ;
BENARI, Y .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 205 (03) :327-328
[4]   Metabotropic glutamate receptors: electrophysiological properties and role in plasticity [J].
Anwyl, R .
BRAIN RESEARCH REVIEWS, 1999, 29 (01) :83-120
[5]   Neuroprotective effects of a systemically active Group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia [J].
Bond, A ;
O'Neill, MJ ;
Hicks, CA ;
Monn, JA ;
Lodge, D .
NEUROREPORT, 1998, 9 (06) :1191-1193
[6]   A novel orally active group 2 metabotropic glutamate receptor agonist: LY354740 [J].
Bond, A ;
Monn, JA ;
Lodge, D .
NEUROREPORT, 1997, 8 (06) :1463-1466
[7]   Metabotropic glutamate receptors and neurodegeneration [J].
Bruno, V ;
Battaglia, G ;
Copani, A ;
Casabona, G ;
Storto, M ;
Gerevini, VD ;
Ngomba, R ;
Nicoletti, F .
GLUTAMATE SYNAPSE AS A THERAPEUTICAL TARGET: MOLECULAR ORGANIZATION AND PATHOLOGY OF THE GLUTAMATE SYNAPSE, 1998, 116 :209-221
[8]   Neuroprotective activity of the potent and selective mGlula metabotropic glutamate receptor antagonist, (+)-2-methyl-4 caroxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlula and mGlu5 receptors [J].
Bruno, V ;
Battaglia, G ;
Kingston, A ;
O'Neill, MJ ;
Catania, MV ;
Di Grezia, R ;
Nicoletti, F .
NEUROPHARMACOLOGY, 1999, 38 (02) :199-207
[9]   ACTIVATION OF METABOTROPIC GLUTAMATE RECEPTORS COUPLED TO INOSITOL PHOSPHOLIPID HYDROLYSIS AMPLIFIES NMDA-INDUCED NEURONAL DEGENERATION IN CULTURED CORTICAL-CELLS [J].
BRUNO, V ;
COPANI, A ;
KNOPFEL, T ;
KUHN, R ;
CASABONA, G ;
DELLALBANI, P ;
CONDORELLI, DF ;
NICOLETTI, F .
NEUROPHARMACOLOGY, 1995, 34 (08) :1089-1098
[10]   PROTECTIVE EFFECT OF THE METABOTROPIC GLUTAMATE-RECEPTOR AGONIST, DCG-IV, AGAINST EXCITOTOXIC NEURONAL DEATH [J].
BRUNO, V ;
COPANI, A ;
BATTAGLIA, G ;
RAFFAELE, R ;
SHINOZAKI, H ;
NICOLETTI, F .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 256 (01) :109-112